8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Apr 28, 2026·SEC
Drugs Made In America Acquisition Corp. functions as a pre-combination shell entity with zero operational revenue and a history of non-operating accounting adjustments that distort its true financial health.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Benchmark DMAA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.89 | $367.18M | 57.32 | — | — | 5.11% | — | |
| $2.79 | $157.03K | -0.00 | -83.94% | 4.58% | 9.62% | — | |
| $1.52 | $1.35M | -0.05 | -10.3% | -3089.55% | -423.84% | — | |
| $4.16 | $1.44B | -6.93 | 698.96% | -88.19% | -49.73% | — | |
| $146.71 | $362.35B | 20.15 | 1.18% | 4.78% | 6.59% | 2.22% | |
| $29.39 | $167.51B | 21.61 | -1.65% | 6.34% | 4.59% | 5.85% |
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
May 1, 2026·SEC
Apr 28, 2026·SEC
Get notified when DMAA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock FAQ — growth, dividends, profitability & financials explained
Yes. Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) earned $6.7M in net income over the trailing twelve months.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) had a return on equity (ROE) of 5.1% in fiscal year 2025. That is below the market's typical 10-15%.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) had negative free cash flow of $0.4M over the trailing twelve months.